EPCAM and neoplasm: Indeed, several anti-EpCAM aptamers have been developed for tumor-targeted drug delivery and have achieved satisfactory outcomes in preclinical and clinical studies.222,223 For example, DOX-loaded mesoporous silica nanoparticles functionalized with EpCAM aptamers can specifically bind to EpCAM-expressing human colon cancer SW620 cells but not to EpCAM-negative Ramos cells.